Your cart is empty.
Synthetic DNA has become the central component of countless scientific and technological innovations across many applications, from biopharmaceuticals to biofuels. However, research and drug development pipelines are often hindered by the cost and the length of time that it takes to obtain long sequences of DNA or multiple DNA variants. Ribbon Biolabs, based in Vienna, is addressing this issue by combining automation and adaptive algorithmic control with highly precise, optimized enzymatic synthesis.
Trauma is the main cause of premature death internationally, resulting in more deaths in people under 40 years old than all other causes combined. Even trauma victims receiving hospital care have a high mortality rate, in part due to massive systemic inflammatory reactions leading to the dysfunction of organs that were not initially injured. A team at Oslo University Hospital in Norway has been investigating the role of the protein HMGB1 (High Mobility Group Box 1) in the development of trauma pathologies and its potential as a clinical biomarker or therapeutic target in these cases.